Company Reports

Qiagen has agreed to an acquisition by private equity firm EQT AB for it to acquire 100% of the company’s shares. The deal is subject to shareholder approval, but both the management and supervisory boards have unanimously recommended acceptance of the all-cash offer price of EUR 46.50 per share.

Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics, and in clinical diagnostics.

Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics and additional activities in clinical diagnostics.

Qiagen named Jonathan Pratt as its new CEO effective Sept. 1, succeeding Thierry Bernard, whose exit was already planned for the second half. Shares fell 5% on the Aug. 24 news.

Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics and additional activities in clinical diagnostics.

Qiagen reported second-quarter constant currency sales growth of 0%, ahead of its own outlook of negative 2%. The adjusted operating margin declined 50 basis points to 29.4%, year over year. Management maintained its full-year outlook.

Qiagen reported first-quarter results below its own outlook, with sales down 1% in constant currencies versus the expected 1% increase. Full-year sales growth guidance was cut to 1%–2% in constant currencies, from at least 5%. Shares trade 4% lower.

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.

Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics, and additional activities in clinical diagnostics.

Qiagen reported fourth-quarter earnings ahead of the PitchBook-compiled consensus, with 1% sales growth in constant currencies and adjusted operating income increasing 80 basis points to 29.5% for full-year 2025.

Bloomberg News reported on Jan. 20 that Qiagen is considering a sale of its business and is in discussions with potential acquirers. The market reacted positively, pushing the share price up more than 15% on the day.

Qiagen reported third-quarter earnings with 5% organic growth and 6% growth on its core products, driven by a strong performance in its diagnostic solutions segment. Management raised its 2025 sales forecast to 4%-5%, up from 4%.

We are transferring the coverage of Qiagen to a new analyst. Qiagen is a well-established supplier of sample preparation technology and kits and is also active in niche end markets like digital PCR and genomics. It is also involved in syndromic molecular diagnostics.

Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics, and additional activities in clinical diagnostics.

Qiagen reported second-quarter 2025 results ahead of company-compiled consensus, with net sales increasing by 6% in constant currency and diluted EPS rising by 9%. Shares are trading 1% lower in US premarket trading.

Qiagen reported first-quarter 2025 results ahead of company-compiled consensus, with revenue up 7% in constant currency and a 410-basis-point improvement in adjusted operating margin to 29.8%. Shares are trading 1% higher intraday.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

Qiagen reported preliminary first-quarter results, with sales and adjusted earnings per share above its previously communicated outlook. Net sales increased 7% during the first quarter, 4% above the guidance, while adjusted EPS of $0.55 came in comfortably above the firm's target of $0.50.

No-moat Qiagen reported solid fourth-quarter 2024 results, in line with company-compiled consensus. For the full year, Qiagen delivered net sales of $1.98 billion, aligning with our model and remaining largely flat compared with 2023 figures. Bottom-line figures for the year showed a decline due to one-off costs associated with the exit from the NeuMoDX PCR testing platform. However, adjusted EPS grew 6% year over year, reaching $2.20 in constant currencies, in line with recent guidance. We maintain our fair value estimate of $53.48 per share and view the stock as slightly undervalued at current levels.

Qiagen's strong third-quarter results exceeded expectations, and we've mildly raised our 2024 assumptions, although not enough to change our fair value estimate, which is based on much longer-term expectations. Also, while we still give Qiagen a no-moat rating, we recognize that operations have improved substantially in recent years even beyond the pandemic, and we expect Qiagen to remain economically profitable for the foreseeable future.